Alnylam Pharmaceuticals, Inc. (ALNY) earnings
ALNY earnings moved a median of -0.33% by the close. Quarterly and annual ALNY reports and results, each read against the price at its own news timestamp. Back to the ALNY overview →
30 measured ALNY earnings events.
Where these ALNY earnings landedvs 30 measured ALNY earnings reactions
| Middle 50% of ALNY earnings reactions | -1.43% to +1.60% |
|---|---|
| Median reaction (to close) | -0.33% |
| Measured reactions | 30 |
Point-in-time · zero look-ahead
Half of the 30 ALNY earnings events with a measured close landed between -1.43% and +1.60%; 40% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress | Press release | -1.62% | -8.27% | |
| Form 10-Q ALNYLAM PHARMACEUTICALS, For: Jun 30 | SEC filing · Form 10-Q | -1.62% | -8.27% | |
| Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results | Press release | -0.64% | +2.11% | |
| Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress | Press release | -3.62% | +0.65% | |
| Form 10-Q ALNYLAM PHARMACEUTICALS, For: Mar 31 | SEC filing · Form 10-Q | -3.62% | +0.65% | |
| Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results | Press release | -0.85% | -3.98% | |
| Form 10-K ALNYLAM PHARMACEUTICALS, For: Dec 31 | SEC filing · Form 10-K | -1.57% | -1.89% | |
| Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress | Press release | +0.60% | -0.10% | |
| Form 10-Q ALNYLAM PHARMACEUTICALS, For: Sep 30 | SEC filing · Form 10-Q | +0.60% | -0.10% | |
| Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results | Press release | +0.88% | +2.25% | |
| Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress | Press release | +10.55% | +12.07% | |
| Form 10-Q ALNYLAM PHARMACEUTICALS, For: Jun 30 | SEC filing · Form 10-Q | +10.55% | +12.07% | |
| Alnylam to Webcast Conference Call Discussing Second Quarter 2025 Financial Results | Press release | +2.16% | +1.09% | |
| Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress | Press release | -3.29% | -0.78% | |
| Form 10-Q ALNYLAM PHARMACEUTICALS, For: Mar 31 | SEC filing · Form 10-Q | -3.29% | -0.78% | |
| Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results | Press release | +1.26% | +1.77% | |
| Form 10-K ALNYLAM PHARMACEUTICALS, For: Dec 31 | SEC filing · Form 10-K | +2.62% | +3.21% | |
| Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity | Press release | -1.99% | -3.20% | |
| Form 10-Q ALNYLAM PHARMACEUTICALS, For: Sep 30 | SEC filing · Form 10-Q | -1.99% | -3.20% | |
| Alnylam to Webcast Conference Call Discussing Third Quarter 2024 Financial Results | Press release | +0.82% | -0.80% | |
| Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period Activity | Press release | -1.20% | +7.44% | |
| Form 10-Q ALNYLAM PHARMACEUTICALS, For: Jun 30 | SEC filing · Form 10-Q | -1.20% | +7.44% | |
| Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results | Press release | -0.27% | -1.64% | |
| Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity | Press release | -1.69% | -0.33% | |
| Form 10-Q ALNYLAM PHARMACEUTICALS, For: Mar 31 | SEC filing · Form 10-Q | -1.69% | -0.33% | |
| Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results | Press release | -0.53% | +0.11% | |
| Form 10-K ALNYLAM PHARMACEUTICALS, For: Dec 31 | SEC filing · Form 10-K | +0.03% | -0.68% | |
| Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity | Press release | -1.97% | -0.50% | |
| Form 10-Q ALNYLAM PHARMACEUTICALS, For: Sep 30 | SEC filing · Form 10-Q | -1.97% | -0.50% | |
| Alnylam to Webcast Conference Call Discussing Third Quarter 2023 Financial Results | Press release | -0.16% | -2.90% |
Keep exploring
More ALNY: analyst actions → · SEC filings → · ALNY overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| ENDOCYTE (ECYT) | 671 | -0.08% | 46% |
| PolarityTE, Inc. (PTE) | 670 | -0.62% | 38% |
| UroGen Pharma Ltd. - Ordinary Shares (URGN) | 664 | +0.13% | 53% |
| Brainstorm Cell Therapeutics Inc. (BCLI) | 660 | 0.00% | 47% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.